Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.45 |
| ▸ | XIAP | P98170 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 4/20 | 0.41 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134415 | 1.00 | ELANE (0.45) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL25637921 | 0.93 | ELANE (0.46) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL21581232 | 0.90 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297466 | 0.90 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297438 | 0.90 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL29463845 | 0.90 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL8615903 | 0.87 | XIAP (0.48) | ELANEXIAPCMA1MLX | |
| SCHEMBL8920639 | 0.87 | XIAP (0.48) | ELANEXIAPCMA1MLX | |
| SCHEMBL17029371 | 0.86 | ELANE (0.40) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297455 | 0.86 | ELANE (0.40) | ELANEXIAPRENCMA1MLX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102044-A1 | SUBSTRATE-BASED PROBES FOR MONITORING PROTEASE ACTIVITY USING MALDI-TOFMS | ZETEO TECH, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739399-A2 | METHODS AND COMPOSITIONS FOR ULTRAVIOLET PROTECTION OF SKIN | Mary Kay, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4734912-A2 | HIGH SEPARATION DUAL PHASE EYE MAKE-UP REMOVER | Mary Kay, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025264660-A1 | COSMETIC COMPOSITION COMPRISING CAFFEINE AND MELATONIN | MARY KAY INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250360075-A1 | TOPICAL COMPOSITIONS AND METHODS | MARY KAY INC. (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4642419-A1 | COSMETIC COMPOSITIONS AND METHODS OF USING SAME | Mary Kay, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025137712-A1 | COSMETIC COMPOSITIONS AND METHODS OF USING SAME | MARY KAY INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250099625-A1 | TANDEM MOLECULAR FLUORESCENCE REPORTERS FOR DETECTION OF TUMOR-INFILTRATING LEUKOCYTES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-27 | — | — | US | disclosed |
| WO-2025014750-A2 | METHODS AND COMPOSITIONS FOR ULTRAVIOLET PROTECTION OF SKIN | MARY KAY INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025006980-A2 | HIGH SEPARATION DUAL PHASE EYE MAKE-UP REMOVER | MARY KAY INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4146158-A1 | COSMETIC COMPOSITION COMPRISING GLUCONOLACTONE AND GLYCOLIC ACID | Mary Kay, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4142684-A1 | COSMETIC COMPOSITIONS AND METHODS COMPRISING PLUMERIA ALBA FLOWER EXTRACT | Mary Kay, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4138775-A1 | TOPICAL COSMETIC COMPOSITIONS | Mary Kay, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4138773-A1 | TOPICAL COSMETIC COMPOSITIONS | Mary Kay, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023279086-A1 | TOPICAL COMPOSITION AGAINST FINE LINES AND WRINKLES | MARY KAY INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3324925-B1 | TOPICAL SKIN FORMULATIONS | MARY KAY INC (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4096619-A1 | LIP COMPOSITION | Mary Kay, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4072513-A1 | HERBAL COSMETIC COMPOSITION FOR TREATING SKIN | Mary Kay, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022192882-A1 | TOPICAL COMPOSITIONS FOR UV PROTECTION | MARY KAY INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220249359-A1 | COSMETIC COMPOSITIONS AND METHODS FOR THEIR USE IN FIRMING SKIN | MARY KAY INC. | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099625-A1 | TANDEM MOLECULAR FLUORESCENCE REPORTERS FOR DETECTION OF TUMOR-INFILTRATING LEUKOCYTES | GZMB, GUSB, MKI67 | ELANE 181/4885XIAP 1492/4885REN 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.